August 15, 2020

The Niche

Knoepfler lab stem cell blog

placental stem cells

4 min read

The birth-related stem cell clinic industry is a serious problem for patients, the stem cell field, and the FDA as the clinics sell more and more of what I think of as “zombie” injections. One of the biggest changes in the last 2 years in the unproven stem cell clinic arena was predicted by the data that Leigh Turner and I published in one of our collaborative papers in which we saw an upward slope in the number of businesses selling amniotic or other …Read More

4 min read

I’ve been blogging about stem cells now for about 8 years and the recent level of hype about and fluffy media coverage of Celularity, the biotech spun out of Celgene, ranks right up here with the most extreme past cases I’ve seen. What is Celularity and who is its leadership? It’s a new biotech focused on placental stem cells with some familiar, well-known leaders including Bob Hariri and Peter Diamandis, and famous tech names on their board including John Scully and Bill Maris, along …Read More

4 min read

ABC News just reported that the FDA is allgedly “cracking down” on the publicly traded company, MiMedx (MDXG), which sells a placental derivative touted for healing powers. The Wall Street Journal is also following the story. According to ABC News: MiMedx is a publically traded, for-profit company that takes donated human placentas — solicited via a website featuring babies and a cartoon butterfly — and turns them into health products. These can be used as skin grafts or injections, and they’re intended to treat inflammation and scar …Read More